Richard Goldberg, MD, Physician-in-Chief of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, presented the first Charles G. Moertel Lecture of the Alliance for Clinical Trials in Oncology during the plenary session of the group’s recent meeting in Chicago.
This is the first annual Moertel lecture being given through the newly merged cooperative group known as the Alliance for Clinical Trials in Cancer, sponsored by the NCI.
The Moertel Lecture was initiated in 1995 by the cooperative group Cancer and Leukemia Group B to honor the legacy of Dr. Moertel, one of the founding fathers of the North Central Cancer Treatment Group. Moertel, a renowned cancer researcher and former director of the Mayo Comprehensive Cancer Center, died in 1994.
During his presentation titled, “Meaningful Outcomes: Lives Saved Due To Clinical Trials in Early Stage Colon Cancer,” Dr. Goldberg discussed Moertel’s work in making the first major discovery on how to increase the surgical cure rate of stage III colon cancer by adding postoperative chemotherapy, and how that initial discovery has led to further improved outcomes over 35 years of additional research. ■
